





PHARMACEUTICAL 2020

RVL Pharmaceuticals plc
Rank 257 of 358

R V L

The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 112% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is -18%, being 55% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	172,630
Cost of Goods Sold	111,630
Intangible Assets	254,841
Liabilities, Current	75,937
Liabilities, Non-Current	272,486
Other Assets	5,546
Other Compr. Net Income	-383
Other Expenses	256,626
Other Liabilities	124
Other Net Income	-17,327
Other Revenues	240,031
Property and Equipment	30,238
Research and Development	32,319
Selling, General and Administrative Expense	93,030

Output Variable	Value in 1000 USD
Assets	463,255
Liabilities	348,547
Expenses	493,605
Revenues	240,031
Stockholders Equity	114,708
Net Income	-270,901
Comprehensive Net Income	-271,092
Economic Capital Ratio	-18%